Table 4.

Progression-free survival and response rate in epidermal growth factor receptor (EGFR) mutation positive patients following first-line treatment. Data from Mitsudomi et al. [2009] and Makato et al. [2010].

	Progression-free survival (months)		Response rate
	Chemotherapy	EGFR-TKI	Chemotherapy	EGFR-TKI
Mitsudomi et al. [2009] Cisplatin-docetaxel versus gefinitib	6.3	9.3	32.2%	62.1%
Makato etal. [2010] Carboplatin-paclitaxel versus gefinitib	5.5	10.4	30.7%	73.7%

TKI, tyrosine kinase inhibitor.